Profile data is unavailable for this security.
About the company
Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.
- Revenue in GBP (TTM)909.26k
- Net income in GBP-7.94m
- Incorporated1996
- Employees43.00
- LocationOndine Biomedical Inc888-1100 Melville StVANCOUVER V6E 4A6CanadaCAN
- Phone+1 (604) 669-0555
- Fax+1 (604) 669-0555
- Websitehttps://ondinebio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abingdon Health PLC | 6.14m | -1.27m | 15.01m | 85.00 | -- | 4.37 | -- | 2.45 | -0.0104 | -0.0104 | 0.0484 | 0.0178 | 1.10 | 6.38 | 4.28 | 72,176.47 | -22.70 | -52.46 | -35.04 | -85.00 | 59.97 | 35.93 | -20.72 | -121.70 | 1.70 | -63.00 | 0.3181 | -- | 51.67 | 21.92 | 63.36 | -- | -15.69 | -- |
| Inspiration Healthcare Group PLC | 34.30m | -9.76m | 15.47m | 224.00 | -- | 0.5531 | -- | 0.4509 | -0.1421 | -0.1421 | 0.4985 | 0.3119 | 0.6557 | 1.54 | 4.11 | 153,120.50 | -18.66 | 1.04 | -22.64 | 1.28 | 44.88 | 47.61 | -28.46 | 1.16 | 1.15 | -1.75 | 0.3472 | -- | -8.74 | 19.43 | -2,318.38 | -- | 32.41 | -- |
| Belluscura PLC | 1.40m | -14.40m | 17.77m | 35.00 | -- | 1.17 | -- | 12.72 | -0.1003 | -0.1003 | 0.0095 | 0.0905 | 0.0742 | 0.3954 | 0.3956 | 39,911.57 | -76.44 | -49.84 | -84.73 | -54.78 | -33.28 | -66.07 | -1,030.73 | -1,277.34 | 2.09 | -10.15 | 0.00 | -- | -40.96 | 27.44 | -127.13 | -- | 41.32 | -- |
| Polarean Imaging PLC | 1.45m | -6.61m | 18.80m | 29.00 | -- | 1.54 | -- | 13.00 | -0.0249 | -0.0249 | 0.0054 | 0.0101 | 0.1075 | 0.5109 | 1.84 | 49,864.84 | -49.18 | -61.45 | -58.32 | -69.17 | 44.78 | 50.68 | -457.39 | -810.92 | 5.24 | -- | 0.0093 | -- | -13.75 | -18.24 | 14.53 | -- | 64.51 | -- |
| Ondine Biomedical Inc | 909.26k | -7.94m | 24.39m | 43.00 | -- | 2,298.54 | -- | 26.82 | -0.036 | -0.036 | 0.0041 | 0.00004 | 0.2859 | 0.5497 | 9.93 | -- | -249.74 | -- | -597.99 | -- | 60.04 | -- | -873.56 | -- | 0.4828 | -- | 0.9487 | -- | 88.56 | -- | 25.60 | -- | -- | -- |
| ANGLE plc | 2.02m | -18.03m | 26.62m | 150.00 | -- | 1.09 | -- | 13.15 | -0.0684 | -0.0684 | 0.0077 | 0.076 | 0.0553 | 0.3117 | 1.21 | 13,493.33 | -49.30 | -- | -55.77 | -- | 69.07 | -- | -890.91 | -- | 4.80 | -- | 0.1469 | -- | 109.99 | -- | 7.17 | -- | -- | -- |
| Renalytix PLC | 2.63m | -35.77m | 26.83m | 80.00 | -- | 0.5253 | -- | 10.19 | -0.4379 | -0.4379 | 0.032 | 0.1523 | 0.0646 | 2.88 | 4.06 | 32,921.05 | -87.73 | -58.25 | -120.00 | -67.03 | 20.60 | -- | -1,358.30 | -1,904.79 | 1.71 | -9.62 | 0.397 | -- | 14.58 | -- | 18.52 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors UK Ltd.as of 30 Jun 2024 | 25.46m | 11.23% |
| Chelverton Asset Management Ltd.as of 31 Dec 2023 | 9.20m | 4.06% |
| CRUX Asset Management Ltd.as of 31 Mar 2024 | 6.97m | 3.07% |
| Premier Fund Managers Ltd.as of 28 Jun 2024 | 3.07m | 1.35% |
| Aegon Asset Management UK PLCas of 31 Jan 2024 | 1.13m | 0.50% |
